This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
|Articles|November 1, 2003
- Pharmaceutical Technology-11-01-2003
- Volume 2003 Supplement
- Issue 5
Understanding Data, Symbol, and Technology Options
Author(s)Dan Mullen
Although the main purpose of the proposed unit-of-use bar coding mandate is to reduce medication errors, manufacturers may find additional benefits to compliance, including reduced materials and finshed-good inventory requirements, improved sample management, and streamlined recalls.
Advertisement
Articles in this issue
about 23 years ago
Improving the Management of Batch Recordsabout 23 years ago
21 CFR Part 11: Where Are We Now?about 23 years ago
Web Services in Pharmaceutical Manufacturingabout 23 years ago
Integrated Compliance ManagementAdvertisement
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
2
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
3
France Remains One of Europe’s Leading Biotech Funding Hubs
4
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
5